Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. A Phase 1a clinical trial has demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Biotechnology

Clinical Trials

Therapeutics

Herantis Pharma Plc.

Antti Vuolanto

Kira Holmström

Ana Raquel Moreira

Natalia Kulesskaya

Riikka Niemi

This department oversees the strategic direction and policies of the organization through its board members.

Board Governance

This department manages office operations and administrative support functions.

Administration

This department oversees the design, implementation, and management of clinical studies and nonclinical pharmacology efforts to advance medical research.

Clinical Research

This department focuses on scientific research and innovation to develop new products and improve existing technologies.

Research and Development

This department oversees the strategic direction and governance of the organization.

Herantis Pharma Plc.

Org chart

Teams

Board Governance

Administration

Clinical Research

Research and Development

Executive Leadership

Offices

Herantis Pharma Plc.

Org chart

Teams

Board Governance

Administration

Clinical Research

Research and Development

Executive Leadership

Offices

Related companies